These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

132 related items for PubMed ID: 8616901

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Lonidamine as a modulator of alkylating agent activity in vitro and in vivo.
    Teicher BA, Herman TS, Holden SA, Epelbaum R, Liu SD, Frei E.
    Cancer Res; 1991 Feb 01; 51(3):780-4. PubMed ID: 1988117
    [Abstract] [Full Text] [Related]

  • 4. Modulation of alkylating agents by lonidamine in vivo.
    Teicher BA, Holden SA, Herman TS, Frei E.
    Semin Oncol; 1991 Apr 01; 18(2 Suppl 4):7-10. PubMed ID: 1903216
    [Abstract] [Full Text] [Related]

  • 5. Etoposide with lonidamine or pentoxifylline as modulators of alkylating agent activity in vivo.
    Tanaka J, Teicher BA, Herman TS, Holden SA, Dezube B, Frei E.
    Int J Cancer; 1991 Jun 19; 48(4):631-7. PubMed ID: 2045206
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Cytotoxicity of lonidamine alone and in combination with other drugs against murine RIF-1 and human HT1080 cells in vitro.
    Ning SC, Hahn GM.
    Cancer Res; 1990 Dec 15; 50(24):7867-70. PubMed ID: 2253227
    [Abstract] [Full Text] [Related]

  • 8. In vitro and in vivo potentiation by lonidamine of the antitumor effect of adriamycin.
    Zupi G, Greco C, Laudonio N, Benassi M, Silvestrini B, Caputo A.
    Anticancer Res; 1986 Dec 15; 6(5):1245-9. PubMed ID: 3800331
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Modulation of cytotoxic drug activity by mitotane and lonidamine in human adrenocortical carcinoma cells.
    Villa R, Orlandi L, Berruti A, Dogliotti L, Zaffaroni N.
    Int J Oncol; 1999 Jan 15; 14(1):133-8. PubMed ID: 9863019
    [Abstract] [Full Text] [Related]

  • 18. Fluorouracil, doxorubicin, and cyclophosphamide versus fluorouracil, doxorubicin, and cyclophosphamide plus lonidamine for the treatment of advanced breast cancer: a multicentric randomized clinical study.
    Calabresi F, Di Lauro L, Marolla P, Curcio CG, Paoletti G, Calabró A, Giannarelli D, Ballatore P, Foggi CM, Di Palma M.
    Semin Oncol; 1991 Apr 15; 18(2 Suppl 4):66-72. PubMed ID: 2031201
    [Abstract] [Full Text] [Related]

  • 19. Ultralow doses of various drugs in chemotherapy of experimental tumors.
    Konovalova NP.
    Bull Exp Biol Med; 2003 Jan 15; 135 Suppl 7():45-7. PubMed ID: 12949646
    [Abstract] [Full Text] [Related]

  • 20. Lonidamine can enhance the cytotoxic effect of cisplatin in human tumour cells and rodent cells.
    Raaphorst GP, Feeley MM, Heller DP, Danjoux CE, Martin L, Maroun JA, De Sanctis AJ.
    Anticancer Res; 1990 Jan 15; 10(4):923-7. PubMed ID: 2382989
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.